drugset
Drugs / NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine
last change Apr 2019 re-read 9 days ago

NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine

Vaccine

Developed for
childhood malignant neoplasm · metastatic neoplasm
Investigated by
Bristol-Myers Squibb · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Jonsson Comprehensive Cancer Center · National Cancer Institute (NCI) · Stand Up To Cancer

Trials 1

today NCT02775292 · Ph 1
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02775292 Jan 2017 → Apr 2019 childhood malignant neoplasm, metastatic neoplasm Jonsson Comprehensive Cancer Center Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02775292 ↗
Modality Vaccine “dendritic cell vaccine” NCT02775292 ↗
Route Other “Patients receive NY-ESO-1(157-165) peptide pulsed DC intradermally (ID) on days 1, 14, and 28.” NCT02775292 ↗